{"id":"https://openalex.org/W4394599236","doi":"https://doi.org/10.1212/wnl.0000000000204375","title":"Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) with Natalizumab Extended Interval Dosing (EID) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH\u00ae Prescribing Program Database (P10-6.005)","display_name":"Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) with Natalizumab Extended Interval Dosing (EID) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH\u00ae Prescribing Program Database (P10-6.005)","publication_year":2024,"publication_date":"2024-04-09","ids":{"openalex":"https://openalex.org/W4394599236","doi":"https://doi.org/10.1212/wnl.0000000000204375"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000204375","doi":"https://doi.org/10.1212/wnl.0000000000204375","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000204375","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068351536","display_name":"Lana Zhovtis Ryerson","orcid":"https://orcid.org/0000-0003-1868-3893","observed_orcids":["https://orcid.org/0000-0003-1868-3893"]},"institutions":[{"id":"https://openalex.org/I4210160846","display_name":"Jersey Shore University Medical Center","ror":"https://ror.org/05pecte80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lana Zhovtis Ryerson","raw_affiliation_strings":["Jersey Shore University Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jersey Shore University Medical Center","institution_ids":["https://openalex.org/I4210160846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027116773","display_name":"John F. Foley","orcid":"https://orcid.org/0000-0003-0431-7067","observed_orcids":["https://orcid.org/0000-0003-0431-7067"]},"institutions":[{"id":"https://openalex.org/I4210109961","display_name":"Rocky Mountain Multiple Sclerosis Clinic","ror":"https://ror.org/015dsp568","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210109961"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Foley","raw_affiliation_strings":["Rocky Mountain MS Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rocky Mountain MS Clinic","institution_ids":["https://openalex.org/I4210109961"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059662648","display_name":"Ilya Kister","orcid":"https://orcid.org/0000-0003-3549-949X","observed_orcids":["https://orcid.org/0000-0003-3549-949X"]},"institutions":[{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ilya Kister","raw_affiliation_strings":["Department of Neurology, NYU Langone Health, New York University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, NYU Langone Health, New York University","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036008316","display_name":"Gary Cutter","orcid":"https://orcid.org/0000-0002-8455-980X","observed_orcids":["https://orcid.org/0000-0002-8455-980X"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary Cutter","raw_affiliation_strings":["University of Alabama at Birmingham School of Public Health"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham School of Public Health","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012380785","display_name":"Ryan R. Metzger","orcid":"https://orcid.org/0000-0003-0906-7108","observed_orcids":["https://orcid.org/0000-0003-0906-7108"]},"institutions":[{"id":"https://openalex.org/I4210109961","display_name":"Rocky Mountain Multiple Sclerosis Clinic","ror":"https://ror.org/015dsp568","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210109961"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Metzger","raw_affiliation_strings":["Rocky Mountain MS Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rocky Mountain MS Clinic","institution_ids":["https://openalex.org/I4210109961"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006177746","display_name":"Judith D. Goldberg","orcid":"https://orcid.org/0000-0003-3758-6976","observed_orcids":["https://orcid.org/0000-0003-3758-6976"]},"institutions":[{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judith Goldberg","raw_affiliation_strings":["Division of Biostatistics, New York University Grossman School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Biostatistics, New York University Grossman School of Medicine","institution_ids":["https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100413896","display_name":"Xiaochun Li","orcid":"https://orcid.org/0000-0002-1547-3041","observed_orcids":["https://orcid.org/0000-0002-1547-3041","https://orcid.org/0000-0003-1109-6119"]},"institutions":[{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaochun Li","raw_affiliation_strings":["Division of Biostatistics, New York University Grossman School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Biostatistics, New York University Grossman School of Medicine","institution_ids":["https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111991808","display_name":"Evan L. Riddle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Evan Riddle","raw_affiliation_strings":["Biogen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025202363","display_name":"Karen Vossen Smirnakis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Smirnakis","raw_affiliation_strings":["Biogen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083265493","display_name":"Rose M. Domingo-Horne","orcid":"https://orcid.org/0000-0002-6427-1139","observed_orcids":["https://orcid.org/0000-0002-6427-1139"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rose Domingo-Horne","raw_affiliation_strings":["Biogen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033319605","display_name":"Tyler Lasky","orcid":"https://orcid.org/0009-0004-7401-1463","observed_orcids":["https://orcid.org/0009-0004-7401-1463"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tyler Lasky","raw_affiliation_strings":["Biogen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen","institution_ids":["https://openalex.org/I1297540436"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5315,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.64446416,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"102","issue":"7_supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10981","display_name":"Cytomegalovirus and herpesvirus research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/progressive-multifocal-leukoencephalopathy","display_name":"progressive multifocal leukoencephalopathy","score":0.9950000047683716},{"id":"https://openalex.org/keywords/natalizumab","display_name":"natalizumab","score":0.9900000095367432},{"id":"https://openalex.org/keywords/extended-dosing-interval","display_name":"extended dosing interval","score":0.9959999918937683},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.625},{"id":"https://openalex.org/keywords/anti-jcv-antibodies","display_name":"anti-JCV antibodies","score":0.8119999766349792},{"id":"https://openalex.org/keywords/jc-virus","display_name":"JC virus","score":0.7889999747276306},{"id":"https://openalex.org/keywords/hazard-ratio","display_name":"hazard ratio","score":0.5559999942779541},{"id":"https://openalex.org/keywords/dosing-interval","display_name":"dosing interval","score":0.5809999704360962},{"id":"https://openalex.org/keywords/treatment-duration","display_name":"treatment duration","score":0.4580000042915344},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.35600000619888306},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.6029999852180481},{"id":"https://openalex.org/keywords/anti-cd52-antibody","display_name":"anti-CD52 antibody","score":0.7590000033378601},{"id":"https://openalex.org/keywords/anti-cd3-antibody","display_name":"anti-CD3 antibody","score":0.5630000233650208},{"id":"https://openalex.org/keywords/anti-cd25-antibody","display_name":"anti-CD25 antibody","score":0.5609999895095825},{"id":"https://openalex.org/keywords/anti-cd19-antibody","display_name":"anti-CD19","score":0.6119999885559082}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.9369103312492371},{"id":"https://openalex.org/C2780644213","wikidata":"https://www.wikidata.org/wiki/Q704930","display_name":"Progressive multifocal leukoencephalopathy","level":3,"score":0.9116127490997314},{"id":"https://openalex.org/C2781004633","wikidata":"https://www.wikidata.org/wiki/Q386119","display_name":"Natalizumab","level":3,"score":0.9035639762878418},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8328753709793091},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.39964917302131653},{"id":"https://openalex.org/C77088390","wikidata":"https://www.wikidata.org/wiki/Q8513","display_name":"Database","level":1,"score":0.3748805522918701},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31583014130592346},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.30235689878463745},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.14494788646697998},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.09843999147415161}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000204375","doi":"https://doi.org/10.1212/wnl.0000000000204375","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000204375","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4367303899","https://openalex.org/W4389373853","https://openalex.org/W3026035733","https://openalex.org/W4389447181","https://openalex.org/W2972262976","https://openalex.org/W2922996161","https://openalex.org/W2804085895","https://openalex.org/W2973164339","https://openalex.org/W4389444710","https://openalex.org/W4379375952"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"update":[2],"the":[3,88,140,161,310,329,348,367,392,417,442,462,508,526,553,582,610,634,726,744,803,852,933,977,1022,1043,1061,1073],"assessment":[4],"of":[5,20,34,92,101,118,123,164,228,282,298,312,331,350,369,394,419,444,464,476,488,500,510,528,545,555,574,584,602,612,636,655,666,677,688,699,710,728,746,763,774,805,854,917,921,935,955,967,979,993,1004,1014,1024,1035,1045,1063,1072,1075,1101,1125,1149,1168],"PML":[6,30,47,68,124,229,271,289],"risk":[7,48,69,272],"with":[8,13,29,44,58,73,125,139,217,230,268,277],"natalizumab":[9,40,165,264],"EID":[10,41,71,102,126,218,231,265],"in":[11,52,76,309,328,347,366,391,416,441,461,507,525,552,581,609,633,650,725,743,802,851,932,976,998,1009,1021,1042,1060,1155,1174],"comparison":[12],"Q4W":[14,50,74,128,220,233,274],"dosing":[15,51,75,114,129,198,299],"using":[16,80,132],"TOUCH":[17,35,62,259,283],"data":[18,36,63],"as":[19,97,112,316,335,354,514,732,809,939,964,983,1028,1049,1067,1098,1122,1146,1165],"June":[21],"30,":[22],"2023.":[23],"Background:":[24],"Natalizumab":[25],"treatment":[26,180],"is":[27,42,266,290],"associated":[28,43,267],"risk.":[31],"Previous":[32],"analyses":[33,149,157,224,281],"have":[37],"demonstrated":[38],"that":[39,263],"significantly":[45,269],"lower":[46,270],"than":[49,219,273],"anti\u2013JC":[53],"virus":[54],"(JCV)":[55],"antibody-positive":[56,78],"patients":[57,79,294],"multiple":[59],"sclerosis.":[60],"Design/Methods:":[61],"were":[64,130,214],"used":[65],"to":[66,793,1088],"estimate":[67],"for":[70,146,288,292,314,319,333,338,352,357,371,382,396,407,421,432,446,452,466,472,512,517,530,541,557,568,586,597,614,625,638,644,730,735,748,759,807,812,856,867,937,949,962,981,986,1026,1031,1047,1052,1065,1077,1096,1120,1144,1163],"compared":[72],"anti-JCV":[77],"3":[81,148,223],"prespecified":[82],"analyses:":[83],"primary":[84],"(EID":[85,95,110,158],"defined":[86,96,111],"by":[87],"last":[89],"18":[90],"months":[91],"treatment),":[93,107],"secondary":[94],"any":[98,104],"prolonged":[99],"period":[100],"at":[103],"time":[105],"during":[106],"and":[108,196,1080],"tertiary":[109],"a":[113,317,336,355,374,399,424,449,469,515,533,560,589,617,641,733,751,790,810,859,984,1029,1050],"history":[115],"consisting":[116],"primarily":[117],"EID).":[119],"Hazard":[120],"ratios":[121],"(HRs)":[122],"versus":[127],"estimated":[131],"adjusted":[133],"Cox":[134],"regression":[135],"models.":[136],"Results:":[137],"Compared":[138],"previous":[141,279],"analyses,":[142],"patient":[143,284],"numbers":[144],"increased":[145],"all":[147,156,278,293],"(range:":[150],"EID,":[151],"9.2%\u201315.8%;":[152],"Q4W,":[153],"1.8%\u20133.0%).":[154],"For":[155],"vs":[159,169,173,177,186,190,194,204,208,212,232],"Q4W),":[160],"mean":[162,179,197],"number":[163],"infusions":[166],"(primary:":[167,234],"66.8":[168],"57.0;":[170],"secondary:":[171,244],"63.2":[172],"40.1;":[174],"tertiary:":[175,250],"43.5":[176],"42.3),":[178],"duration":[181],"(in":[182,200],"months:":[183],"primary,":[184,202],"76.8":[185],"55.7;":[187],"secondary,":[188,206],"70.0":[189],"38.4;":[191],"tertiary,":[192,210],"57.8":[193],"42.0),":[195],"interval":[199,239],"days:":[201],"36.6":[203],"30.1;":[205],"35.5":[207],"29.9;":[209],"42.3":[211],"30.8)":[213],"numerically":[215],"greater":[216],"dosing.":[221],"All":[222],"showed":[225],"reduced":[226],"risks":[227],"87%":[235],"[HR=0.134":[236],"(95%":[237],"confidence":[238],"[CI],":[240],"0.064\u20130.279),":[241],"P":[242,248,254],"<0.0001];":[243,249],"81%":[245],"[HR=0.189":[246],"(0.106\u20130.337),":[247],"97%":[251],"[HR=0.035":[252],"(0.006\u20130.195)],":[253],"=0.0001).":[255],"Conclusions:":[256],"This":[257],"updated":[258],"database":[260],"analysis":[261],"demonstrates":[262],"dosing,":[275],"consistent":[276],"annual":[280],"data.":[285],"Vigilant":[286],"monitoring":[287],"important":[291],"receiving":[295],"natalizumab,":[296],"regardless":[297],"interval.":[300],"Disclosure:":[301],"Dr.":[302,321,340,359,384,409,434,454,477,489,501,519,546,575,603,627,646,656,667,678,689,700,711,719,737,764,775,783,796,845,926,956,970,994,1005,1090,1103,1138,1151],"Zhovtis":[303,322,341,360,385,410,435,455,478,490],"Ryerson":[304,323,342,361,386,411,436,456,479,491],"has":[305,324,343,362,387,412,437,457,480,492,503,521,548,577,605,629,648,658,669,680,691,702,713,721,739,766,777,785,798,847,928,958,972,996,1007,1017,1038,1056,1086,1092,1105,1116,1129,1140,1153,1159,1172],"received":[306,325,344,363,388,413,438,458,481,493,504,522,549,578,606,630,659,670,681,692,703,714,722,740,767,778,786,799,848,929,959,973,1018,1039,1057,1093,1106,1117,1130,1141,1160],"personal":[307,326,345,364,389,414,439,459,505,523,550,579,607,631,723,741,800,849,930,960,974,1019,1040,1058,1094,1118,1142,1161],"compensation":[308,327,346,365,390,415,440,460,506,524,551,580,608,632,724,742,801,850,931,961,975,1020,1041,1059,1095,1119,1143,1162],"range":[311,330,349,368,393,418,443,463,509,527,554,583,611,635,727,745,804,853,934,978,1023,1044,1062],"$5,000-$9,999":[313,370,529,729,806,855],"serving":[315,334,353,372,397,422,447,467,513,531,558,587,615,639,731,749,808,857,938,963,982,1027,1048,1066,1097,1121,1145,1164],"Consultant":[318,337,356,516,734,811,985,1030,1051],"Biogen.":[320,383,485,542,645,663,1102,1113,1126,1137,1150,1156,1169,1175],"$500-$4,999":[332,351,395,420,445,465,511,556,585,613,747,936],"Novartis.":[339,433,473,674,782],"Genentech.":[358,408,497,696,771],"on":[373,398,423,448,468,532,559,588,616,640,750,858],"Scientific":[375,400,425,534,561,590,618,752,860],"Advisory":[376,401,426,535,562,591,619,753,861,946],"or":[377,402,427,536,563,592,620,754,862,944,1070,1108,1132],"Data":[378,403,428,537,564,593,621,755,863],"Safety":[379,404,429,538,565,594,622,756,864],"Monitoring":[380,405,430,539,566,595,623,757,865],"board":[381,406,431,540,567,596,624,758,866],"Speakers":[450,470,642],"Bureau":[451,471,643],"Sanofi.":[453],"The":[474,486,498,543,572,600,653,664,675,686,697,708,761,772,1012,1033],"institution":[475,487,499,544,573,601,654,665,676,687,698,709,762,773,1013,1034],"research":[482,494,660,671,682,693,704,715,768,779],"support":[483,495,661,672,683,694,705,716,769,780],"from":[484,496,662,673,684,695,706,717,770,781,789,1112,1136],"Foley":[502,520,547,576,604,628,647,657,668,679,690,701,712],"Octave.":[518,685],"TG":[569,843],"Therapeutics":[570],".":[571],"Horizon":[598,891],"Therapeutics.":[599,844],"Sandoz.":[626],"$10,000-$49,999":[637,980,1025,1046,1064],"stock":[649,997,1008,1107,1131,1154,1173],"InterPRO":[651],"Bioscience.":[652,988],"Imstem.":[707],"Aegir.":[718],"Kister":[720,738,765,776,784],"Genentech-Roche.":[736],"Horizon.":[760],"publishing":[787],"royalties":[788],"publication":[791],"relating":[792],"health":[794],"care.":[795],"Cutter":[797,846,927],"Biodelivery":[813],"Sciences":[814],"International,":[815],"Biogen,":[816],"Click":[817],"Therapeutics,":[818,869,880,895],"Genzyme,":[819],"Genentech,":[820],"GW":[821],"Pharmaceuticals,":[822,834,838,841,876,887,892,911],"Immunic,":[823,893],"Klein-Buendel":[824],"Incorporated,":[825],"Medimmune/Viela":[826],"Bio,":[827],"Medday,":[828],"Merck/Serono,":[829],"Neurogenesis":[830],"LTD,":[831,898],"Novartis,":[832,907],"Osmotica":[833],"Perception":[835],"Neurosciences,":[836],"Recursion/Cerexis":[837],"Regeneron,":[839,908],"Reckover":[840],"Roche,":[842],"Applied":[868],"AI":[870],"therapeutics,":[871],"AMO":[872],"Pharma,":[873,890],"Astra-Zeneca,":[874],"Avexis":[875],"Biolinerx,":[877],"Brainstorm":[878],"Cell":[879],"Bristol":[881],"Meyers":[882],"Squibb/Celgene,":[883],"CSL":[884],"Behring,":[885],"Galmed":[886],"Green":[888],"Valley":[889],"Karuna":[894],"Mapi":[896],"Pharmaceuticals":[897],"Merck,":[899],"Mitsubishi":[900],"Tanabe":[901],"Pharma":[902],"Holdings,":[903],"Opko":[904],"Biologics,Prothena":[905],"Biosciences,":[906],"Sanofi-Aventis,":[909],"Reata":[910],"NHLBI":[912],"(Protocol":[913],"Review":[914],"Committee),":[915],"University":[916,920],"Texas":[918],"Southwestern,":[919],"Pennsylvania,":[922],"Visioneering":[923],"Technologies,":[924],"Inc.":[925,1083],"an":[940,965,1068,1099,1109,1123,1133,1147,1166],"Editor,":[941,943],"Associate":[942],"Editorial":[945],"Board":[947,1074],"Member":[948],"JASN.":[950],"An":[951,989,1000],"immediate":[952,990,1001],"family":[953,991,1002],"member":[954,992,1003,1071],"Metzger":[957,971,995,1006],"employee":[966,1100,1124,1148,1167],"Neurocrine":[968,1010],"Biosciences.":[969,1011],"Interpro":[987],"Ascendis.":[999],"Judith":[1015,1036,1054],"Goldberg":[1016,1037,1055],"Amarin.":[1032],"Asieris.":[1053],"officer":[1069],"Directors":[1076],"Statistical":[1078],"Science":[1079],"Technology":[1081],"Associates,":[1082],"Xiaochun":[1084],"Li":[1085],"nothing":[1087],"disclose.":[1089],"Riddle":[1091,1104],"ownership":[1110,1134],"interest":[1111,1135],"Karen":[1114,1127],"Smirnakis":[1115,1128],"Domingo-Horne":[1139,1152],"Tyler":[1157,1170],"Lasky":[1158,1171]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2}],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2024-04-10T00:00:00"}